ArticleAnnals of translational medicine2019
No paradigm changes with checkpoint inhibitor monotherapy in patients with metastatic renal cell carcinoma and brain metastases.
Sergio Bracarda et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.